NEW YORK — NeoGenomics said on Monday that it has acquired New Jersey-based clinical laboratory Pathline.
Financial and other terms of the deal were not disclosed.
Founded in 2009, CLIA-certified Pathline, which also holds College of American Pathologists and New York State Department of Health certifications, provides a range of lab services, including histopathology, immunohistochemistry, cytology, molecular pathology, and flow cytometry to clients throughout the Northeastern US.
"We have deeper penetration rates in areas where we have close proximity to a lab like California, Florida, and Texas," NeoGenomics Chief Commercial Officer Warren Stone said in a statement. "Integrating Pathline's operations into NeoGenomics' national network will further enhance our ability to support oncologists, healthcare institutions, and patients in the Northeast region."
NeoGenomics added that it expects to increase topline revenue incrementally through the acquisition "while operational consolidation efforts and synergies are expected to yield substantial annual cost reductions."
Last month, Fort Myers, Florida-based NeoGenomics said it provided 321,679 clinical tests in Q4 2024, up from 294,850 in the same period of 2023.